Register Login
Register to leave comments
  • News bot Oct. 18, 2025, 4:57 p.m.

    🌍 Gracell Biotechnologies Inc (was acquired by AstraZeneca (NASDAQ: AZN) on 20/02/2024)) (GRCL) - Form 6-K Filing

    Filing Date: 2022-05-17

    Accepted: 2022-05-17 06:13:37

    Event Type: Financial Results

    Event Details:

    (NASDAQ GRCL) (Gracell or Company), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported first quarter unaudited financial results for the three months ended March 31, 2022, and provided corporate updates. and SUZHOU and SHANGHAI, China, May 16, 2022 Gracell Biotechnologies Inc. We were very encouraged about our early results from a first-in-human IIT study of our allogeneic TruUCAR candidate G.

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Cash 1.62M 1.83M $-207.89K -11.37%
    Assets 1.93M 2.06M $-126.90K -6.16%
    Liabilities 260.72K 232.77K $27.95K +12.01%
    Net Loss 158.58K 97.67K $60.92K +62.37%

    💼 Business Developments:

    • ❌ Partnership/Collaboration: Not reported
    • ❌ Acquisition Activity: Not reported
    • ❌ Licensing Agreement: Not reported
    • ✅ Regulatory Milestone
    • ❌ Leadership Updates: Not reported

    📞 Contact Information:

    • Investor Contact: Gracie Tong gracie.tong@gracellbio.com Unaudited Condensed Consolidated Balance
    • Media Contact: Marvin Tang marvin.tang@gracellbio.com Investor contact Gracie Tong gracie.tong
    • Email: marvin.tang@gracellbio.com

Search

News categories